Artivion (AORT) Cuts Guidance Following AMDS Slower Adoption, Is It Still Below Fair Value?
Artivion (AORT) is back in focus after the company cut its full year guidance, citing slower than expected adoption of its AMDS product, despite reporting 12% non GAAP constant currency revenue growth in Q1 2026.
See our latest analysis for Artivion.
At a share price of $25.37, Artivion has seen a 19.73% 1 month share price return and a 5.58% 7 day share price return, although the 90 day share price return is down 30.61% and the year to date share price return is down 42.94%. The 3 year total shareholder return of 51.10% contrasts with a 1 year total shareholder return decline of 17.20%, suggesting recent momentum has faded after stronger medium term gains.
If you are reassessing growth stories after Artivion's guidance cut, it can help to broaden your search and review the 39 healthcare AI stocks
Artivion has a broad aortic portfolio and solid recent revenue and net income growth, yet the share price has swung sharply after the guidance cut. Is this still a strong business now being offered at an attractive valuation, or not?
Most Popular Narrative: 40% Undervalued
Artivion's most followed narrative pegs fair value at $42 per share, well above the last close of $25.37, and builds its case on earnings expansion and a richer future profit multiple.
Ongoing U.S. launch of AMDS, with positive physician feedback, rapid clinical adoption post-training, and a significant $150 million annual market opportunity, indicates accelerating market penetration, this should materially contribute to both top-line revenue growth and high-margin product mix, improving EBITDA margins long-term.
Want to see why this narrative backs a much higher price for Artivion? It leans heavily on faster earnings growth, rising margins, and a premium future P/E that assumes investors will pay up for that trajectory.
Result: Fair Value of $42 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, AMDS adoption could fall short of expectations, and Artivion's debt load and potential equity issuance leave less room if execution or market conditions disappoint.
Find out about the key risks to this Artivion narrative.
Another View: Artivion Looks Expensive On Earnings
Analysts see upside for Artivion using their fair value frameworks, but the current P/E of 105.5x is far above the US Medical Equipment industry at 27.2x and the peer average at 29.9x. It is also well above a fair ratio of 37.4x. That gap points to valuation risk if expectations reset.
For a closer look at how this earnings based view stacks up against growth and quality metrics, review the See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the split views on Artivion, it makes sense to review the underlying data yourself and decide whether the recent reset matches your risk tolerance. To see what is driving optimism in the story, take a closer look at the 3 key rewards
Looking for more investment ideas beyond Artivion?
If Artivion has you rethinking your next move, now is the time to widen your watchlist and pressure test fresh stock ideas with clear, data driven filters.
- Target potential value opportunities by scanning companies that screen well on cash flows and balance sheet strength using the 45 high quality undervalued stocks.
- Strengthen your defensive side by reviewing companies with resilient finances through the solid balance sheet and fundamentals stocks screener (48 results).
- Hunt for under followed opportunities by running the screener containing 20 high quality undiscovered gems before the rest of the market starts paying attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com